Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assay System Validated for Opportunistic Virus Infections

By LabMedica International staff writers
Posted on 31 Oct 2012
Laboratory-developed real-time polymerase chain reaction (PCR) protocols have been implemented for the molecular diagnosis of opportunistic DNA virus infections. More...


The validity of a duplex real-time PCR protocols for viral DNA have been improved by using an extraction and amplification control that allows for the monitoring of the molecular diagnostic process.

Virologists at the Pierre and Marie Curie University (Paris, France) tested 152 clinical samples including 77 whole bloods, 30 bronchoalveolar lavages, 28 viral transport medium containing mucocutaneous swabs, 12 urine, and 5 stool samples. The genomes of herpes simplex virus (HSV), varicella-zoster virus (VZV), human cytomegalovirus (CMV), Epstein–Barr virus (EBV), BK virus (BKV), and adenovirus (AdV) were investigated.

The Simplexa extraction and amplification control (SEAC) set (Eurobio; Courtaboeuf, France) was evaluated in this study. This internal control corresponds to a 577-base pair DNA fragment derived from the gene encoding ribulose-1,5-bisphosphate carboxylase oxygenase large unit N-methyltransferase of the plant Arabidopsis thaliana. This is a noncompetitive internal control with its own mix, containing primers and a Quasar 670 labeled-probe specifically designed for its amplification (Biosearch Technologies; Novato, CA, USA). Viral DNA amplifications were performed on the Light cycler LC480 system (Roche Diagnostics; Meylan, France) using laboratory-developed real-time PCR assays based on hydrolysis probe technology implemented in the laboratory for virological diagnosis activity.

The SEAC results showed high reproducibility with a mean crossing point (Cp) value of 31.08 ± 1.44, and were not influenced by the virus-specific PCR performed or the type of clinical specimen tested. The use of the SEAC did not influence the results of the different virus-specific PCRs compared to other systems. The SEAC in the DNA extracts showed high stability during storage at both +4 °C and -20 °C.

The authors concluded that the use of the commercial SEAC is simple, straightforward, and beneficial. It makes not only the detection of opportunistic viruses in clinical samples more convenient and cost-effective, but it ensures also the effectiveness of the whole molecular process implemented in the laboratory to perform the diagnosis of viral infections. The SEAC provides a reliable option to improve the diagnosis of opportunistic viral infections in laboratories using in-house real-time PCR assays. The study was published in the October 2012 edition of the Journal of Virological Methods.

Related Links:
Pierre and Marie Curie University
Eurobio
Biosearch Technologies


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.